Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Skin Barrier Function in Pediatric Atopic Dermatitis (PELISTAD)
NCT04718870Phase 4Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04718870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718870.